aspr U.S. Department of Health & Human Services
  Public Health Emergency
BARDA Stakeholder Portal

PARTNERING ON VACCINES TO COUNTER MULTI-DRUG RESISTANT (MDR) THREATS

BARDA's CBRN Division seeks partners for its Vaccine Portfolio

Let's Work Together to Develop a Vaccine

icon magnifying glass Review Market Research Workshop
icon paper Submit proposal
icon hand and vaccine Partnering Pre-IND to late stage Vaccine Development (BARDA)
icon FDA and ribbon FDA vaccine review and licensure
icon people standing Vaccines will Save Lives
Learn More

The Challenge

Multi-drug resistant (MDR) organisms are a threat to national security and public health. As rates of antimicrobial resistance (AMR) in pathogens continue to increase new therapeutics and vaccines are essential to combat the growing crisis.

The Situation

Every year, 2.8 million American develop a drug resistant infection and 35,000 people die. Globally, MDR infections kill 700,000 each year - current estimates are that MDR organisms will kill more than 10 million a year by 2050 if left unchecked.

BARDA's Impact

BARDA supports development and procurement of medical countermeasures to protect Americans against chemical, biological, radiological, and nuclear (CBRN) threats. MDR does not discriminate, and victims of CBRN events are at risk of suffering fatal complications from drug resistant infections. One of BARDA’s top priorities is to develop a vaccine to protect people from these threats.

TWO WAYS BARDA CAN HELP YOU ON YOUR ANTIBACTERIAL VACCINE CANDIDATE

The BARDA Antibacterials program is well known for investments in small molecules since its launch in 2010, including supporting FDA approval of three antibiotics. But BARDA’s investments go beyond antibiotics. The BARDA CBRN Vaccine program has invested in efforts that led to FDA licensure of vaccines against smallpox and Ebola. And through CARB-X, the portfolio has expanded to include non-traditional products and currently supports the development of four vaccines.

Vaccines against MDR Threats-BARDA BAA

Through the existing BAA (BAA-18-100-SOL-00003), BARDA is looking to support programs for vaccines for MDR pathogens in the late preclinical stage through phase II clinical development.

Learn more or apply
BARDA Logo
CARB-X

BARDA partners with CARB-X for support of preclinical development of vaccines for MDR/DR pathogens. CARB-X is a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.

More information about CARB-X

BARDA's Pathogens of Interest: These four pathogens are among the top public health threats because of their cost, incidence, morbidity and mortality, and their overlap with other public health emergencies. AMR can hinder emergency response by worsening outcomes, regardless of root cause.

Escherichia coli

Klebsiella pneumoniae

Pseudomonas aeruginosa

Staphylococcus aureus

What is BARDA Looking for in a Vaccine Candidate?

Vaccine Against Drug Resistant Threats Requirements

  • Vaccine against one of the following: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus
  • Within 1-year of Investigational New Drug (IND) submission or open IND - focus on Late-preclinical to early clinical development
  • Cost-sharing

Note: Updates to BAA pending. Klebsiella pneumoniae will be added and Acinetobacter baumannii will be removed


MORE INFORMATION OR APPLY

person holding vial and syringe

BARDA's Vaccine Market Research Workshop

Thank you to everyone who joined us on March 12, 2021! We had a great discussion with the group and are looking forward to hearing about your products in the future. If you are developing a vaccine that address one of the four pathogens of interest, please consider requesting a TechWatch meting with us to discuss your candidate.

BARDA Vaccine Market Research Workshop
Learn about BARDA’s plan to tackle this growing threat and how you can help!
Recorded March 12, 2021
View Workshop Agenda